Triple Artemisinin-Based Combination Therapy (TACT) is a promising advancement in the global fight against malaria, offering enhanced efficacy, reduced resistance, and broader therapeutic applications. This review highlights the potential of TACT in malaria control and eradication, emphasizing its advantages over traditional Artemisinin-Based Combination Therapies (ACTs). TACT addresses drug resistance, provides a broader spectrum of action, reduces treatment failure risk, and can be tailored to regional needs. However, its effectiveness depends on accessibility, particularly in resource-limited areas. Collaborative efforts among stakeholders, sustainable pricing, efficient supply chains, and public-private partnerships are essential to ensure TACT reaches those in need. Health education campaigns are crucial to dispel malaria myths and promote TACT acceptance. TACT has shown promising results in clinical trials, demonstrating non-inferiority to ACT in efficacy and similar safety profiles. It reduces the risk of reinfection and delays the development of drug resistance. However, TACT may not be a long-term solution, as resistance can develop. Therefore, it should be used in conjunction with complementary strategies such as enhanced surveillance, vector control, and new drug development. TACT is generally safe and well-tolerated, though some side effects like vomiting and QTc interval prolongation may occur. Efforts to minimize side effects and improve patient adherence involve minimizing drug interactions and educating patients and healthcare providers. Governments and global organizations should consider subsidizing TACT costs to ensure affordability and accessibility. TACT's global impact depends on its accessibility, which requires collaboration among stakeholders, efficient supply chains, and public-private partnerships. Health education and community engagement are vital to ensure TACT is accepted and used effectively. Challenges in TACT adoption include cost, availability, and ethical considerations, particularly in regions with existing ACT resistance. TACT represents a significant step forward in malaria control, offering improved treatment efficacy and potential to delay drug resistance. However, its success depends on accessibility, sustainable pricing, and effective implementation strategies. Collaboration among governments, international organizations, research institutions, and local communities is essential to achieve malaria control and eradication goals.Triple Artemisinin-Based Combination Therapy (TACT) is a promising advancement in the global fight against malaria, offering enhanced efficacy, reduced resistance, and broader therapeutic applications. This review highlights the potential of TACT in malaria control and eradication, emphasizing its advantages over traditional Artemisinin-Based Combination Therapies (ACTs). TACT addresses drug resistance, provides a broader spectrum of action, reduces treatment failure risk, and can be tailored to regional needs. However, its effectiveness depends on accessibility, particularly in resource-limited areas. Collaborative efforts among stakeholders, sustainable pricing, efficient supply chains, and public-private partnerships are essential to ensure TACT reaches those in need. Health education campaigns are crucial to dispel malaria myths and promote TACT acceptance. TACT has shown promising results in clinical trials, demonstrating non-inferiority to ACT in efficacy and similar safety profiles. It reduces the risk of reinfection and delays the development of drug resistance. However, TACT may not be a long-term solution, as resistance can develop. Therefore, it should be used in conjunction with complementary strategies such as enhanced surveillance, vector control, and new drug development. TACT is generally safe and well-tolerated, though some side effects like vomiting and QTc interval prolongation may occur. Efforts to minimize side effects and improve patient adherence involve minimizing drug interactions and educating patients and healthcare providers. Governments and global organizations should consider subsidizing TACT costs to ensure affordability and accessibility. TACT's global impact depends on its accessibility, which requires collaboration among stakeholders, efficient supply chains, and public-private partnerships. Health education and community engagement are vital to ensure TACT is accepted and used effectively. Challenges in TACT adoption include cost, availability, and ethical considerations, particularly in regions with existing ACT resistance. TACT represents a significant step forward in malaria control, offering improved treatment efficacy and potential to delay drug resistance. However, its success depends on accessibility, sustainable pricing, and effective implementation strategies. Collaboration among governments, international organizations, research institutions, and local communities is essential to achieve malaria control and eradication goals.